Several cardiac resident progenitor cell types have been reported for the adult mammalian heart. Here we characterize their frequencies and distribution pattern in non-ischaemic human myocardial tissue and after ischaemic events.
Introduction
Stem cell-based therapies might be therapeutic alternatives for the restoration of myocardial function after damage or disease, which are highly desirable as the heart lacks significant endogenous regenerative potential. 1, 2 With increasing knowledge of stem cellbased therapies, new hope has arisen for the treatment of heart failure. Various stem cell types are undergoing evaluation including haematopoietic stem cells, 3 endothelial progenitors, 4 mesenchymal stem cells (MSCs), 5 and the so-called SP cells. 6, 7 Furthermore, skeletal myoblasts 8 as well as embryonic stem cells (ESC) 9 or induced pluripotent stem cells (iPS) 10, 11 are being considered.
However, the lack of efficacy, non-specific differentiation, clinical safety issues as well as the ethical debate over ESC still limit clinical application and underline the demand for cardiac-specific stem cell types.
Recent data indicate that the heart hosts its own stem/progenitor cell populations 12 -14 with the capacity to differentiate along all cardiac cell lineages. 13, 15, 16 These cardiac resident progenitor cells (CRPC) include primitive cells expressing the stem-cell-factor receptor c-kit (CD117) 16 , and Sca-1 + cells detected in mice 12 and in humans. 17 Despite their frequent denomination as stem cells, not all these cell types were demonstrated to fulfil the criteria of bona fide stem cells as being self-renewing, clonogenic, and multipotent. 18 Martin et al. detected cardiac side population (cSP) cells in the heart. 19 Side population cells can be isolated by dualwavelength flow cytometry because of their capacity to efflux Hoechst dye, a process mediated by the ATP-binding cassette transporter breast cancer resistance protein (BCRP). 6, 7 Breast cancer resistance protein (also known as ABCG2) has been recently reported to play a functional role in modulating the proliferation, differentiation, and survival of cSP cells, 20 but is also present within endothelial cells of the human heart. 21 Another CRPC population was isolated by Messina et al. 22 from murine and human hearts. They were the first to demonstrate extensive in vitro proliferation of the isolated cells in so-called cardiosphere cultures. In vitro cultivation of CRPC might be a decisive step forward for future myocardial restoration requiring large cell numbers.
The expression pattern and frequency of CRPC in a healthy or diseased human heart has not been explored so far. Herein we identify and quantify of human BCRP + and c-kit + cells in the different compartments of the heart and ischaemic vs. non-ischaemic myocardium, and assess whether human BCRP + cells can be considered cardiac progenitor cells. The detailed clarification of the distribution and frequencies of CRPC in ischaemic and nonischaemic heart samples might have an important impact on effective stem cell treatment strategies in the future.
Methods

Patient demographics
After informed consent, 55 tissue-samples were obtained from 50 patients (male ¼ 32/female ¼ 18). The patients were Caucasians (17-83 years) and suffered either from ischaemic heart disease (n ¼ 33) or non-ischaemic heart-diseases, including valve-disease (n ¼ 13), non-ischaemic, dilative cardiomyopathy (n ¼ 2), and congenital heart disease (n ¼ 2). Except three emergency cases including two left ventricular assist device (LVAD) implantations due to ischaemic cardiomyopathy (n ¼ 2) and one coronary artery bypass grafting (CABG) for instable angina (n ¼ 1) within the ischaemic group, and two heart transplantations due to dilated cardiomyopathy (n ¼ 2) in the nonischaemic group, all the patients were elective cases. The treatment included aspirin, angiotensin-converting enzyme inhibitors, betablockers, and others. The demographics are summarized in Table 1 .
Tissue samples
Tissue samples sized 5 × 5 mm were harvested from all areas of the heart. They were obtained from the right atrium (n ¼ 36) after cannulation during coronary artery bypass grafting (CABG). Endomyocardial biopsy samples of the left atrium (n ¼ 4), left ventricle (n ¼ 10), and right ventricle (n ¼ 5) were taken during CABG and all other open heart procedures. For ischaemic patients, after careful intra-operative macroscopic evaluation, biopsy samples were harvested from the border zone of the ischaemic/infarcted area of the left ventricle, but not directly from the infarcted area. The samples were fixed in 4% paraformaldehyde for 2 h following 24 h in 30% sucrose, embedded in TissueTek (Sakura-Finetek), frozen in liquid nitrogen, and cut into 6-mm sections.
Immunostaining and cell counts
For a quantitative analysis of progenitor cell frequencies, immunostaining was performed in at least four sections of each tissue sample. The positive controls were as follows: BCRP + trophoblast cells in human placenta (see Supplementary material online, Figure S1A ), c-kit + melanocytes in human skin (see Supplementary material online, Figure S1B ), c-kit In vitro differentiation of breast cancer resistance protein 1 cells
The cells were seeded into 24well plates (Nunc/Thermo Fisher Scientific) after coating with Matrigel (1:30, BD Biosciences, Heidelberg, Germany), and the cell culture medium consisted of 80% IMDM (with Glutamax), 20% foetal calf serum (HyClone/Thermo Fisher Scientific, Bonn, Germany), 1 mM L-glutamine, 0.1 mM b-mercaptoethanol, 1% non-essential amino acids, 100 mg/mL penicillin, and 100 mg/mL streptomycin (from PAA Laboratories, Coelbe, Germany). Twenty-four hours after seeding, the cells were treated with 100 nM oxytocin (Sigma-Aldrich, Munich, Germany) for 72 h as described by Oyama et al.
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Gene expression analysis
Quantitative real-time PCR was used to determine the gene expression of BCRP + cells after in vitro differentiation. These procedures are described in detail in the Supplementary material online, Methods.
Statistical analysis
Descriptive data are presented as mean + standard deviation or median with range where appropriate. For statistical analysis using SPSS 18 (SPSS, Inc., Chicago, IL, USA), the Mann-Whitney test was performed. To avoid biased estimates for patients that provided more than one cardiac sample (n ¼ 3), medians of samples within patients were computed and a patient-specific (n ¼ 50) MannWhitney test was performed. Significance was evaluated by two-tailed testing and assumed to be P , 0.05.
Results
Morphological assessment of putative progenitor cells detected in the heart
Breast cancer resistance protein + /CD31 2 cells were identified in all areas of the heart, appearing mostly small and oval shaped. They were distributed evenly over the whole microscopic field ( Figure 1A -C ). The major part of these cells did not stain positive for the cardiac marker titin, but were located either between or in close relation to the surrounding cardiomyocytes as well as in the interstitial space. However, also titin-positive BCRP + /CD31 
Distribution and frequencies
Breast cancer resistance protein + /CD31 2 cells were found more frequently in ischaemic hearts (n ¼ 33) vs. non-ischaemic (n ¼ 22) hearts with a median of 5.38% (range: 2.48-11.1%) vs. 3.57% (0-7.75%) (P ¼ 0.026) ( Figure 3A) . In the atria, the highest frequency of BCRP + /CD31 2 cells was detected in the right atria of the ischaemic group (n ¼ 26) with a median of 5.40% (2.48-11.10%) vs. 4.40% (1.79-7.75%) (P ¼ 0.47) in the non-ischaemic group (n ¼ 10) ( Figure 3B ). Also in the ventricles, a significantly increased number of BCRP + /CD31 2 cells was detected in ischaemic ventricles (n ¼ 6) compared with non-ischaemic ventricles (n ¼ 9) with a median of 5.44% (3.24-9.30%) vs. 0.74% (0-5.23%), respectively (P ¼ 0.016) ( Figure 3C ). Isolation and in vitro differentiation of breast cancer resistance protein 1 cells
Using immunomagnetic bead separation, cells were enriched from dissociated human heart samples (n ¼ 6) on the basis of their expression of the surface marker BCRP. Co-purified adult human cardiomyocytes did not adhere to the cell culture dishes (see Supplementary material online, Figure S9A ) and were removed upon medium exchange. Breast cancer resistance protein + and BCRP 2 cells were cultivated on matrigel-coated plates in differentiation medium. Breast cancer resistance protein 2 cell fractions showed higher proliferation rates than BCRP + cells and were frequently overgrown with fibroblast-like cells during cultivation (see Supplementary material online, Figure S9B-D) . To test for differentiation potential as described by Oyama et al. 24 in the rat model, the cells were treated with 100 nM oxytocin for 72 h. However, no spontaneous beating of isolated cells was observed during cultivation for 21 days ( Figure 6A-C) . After 21 days, no cTnT expression was detected in BCRP 2 cells by immunostaining ( Figure 6D ). In contrast, the majority of BCRP + cells stained positive for cTnT ( Figure 6E and F ) , with a diffuse and/or a punctuate dotted linear staining pattern ( Figure 6F) . Interestingly, BCRP + cells not treated with oxytocin seemed to display a similar differentiation capacity, a direct comparison of oxytocin-treated with untreated cells is given in Supplementary material online, Figure S10 . Figure S10E ). However, it has to be noted that the small sample number and size did not allow statistical analysis or the evaluation of other markers of cardiac differentiation.
Discussion
It was proposed that the cardiac SP cell population functions as a progenitor cell population for the development, maintenance, and Higher frequencies of BCRP + cardiac resident cells repair of the heart. 19 Oyama et al. 24 were the first to demonstrate that cSP cells from post-natal rat hearts can differentiate into spontaneously beating cardiomyocytes after induction with non-toxic/-carcinogenic reagents such as oxytocin, as well as into other cell lineages, including endothelial cells and smooth muscle cells. These results support the concept that BCRP + /CD31 2 SP cells might be a possible source for regeneration.
Breast cancer resistance protein 1 cells in the adult human heart
In this study, BCRP + /CD31 2 cells were detected in the atrial tissue of ischaemic but also in non-ischaemic patients at very similar levels. From a clinical point of view, the occurrence of CRPC even in non-ischaemic atria as described by Urbanek et al.
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poses an excellent opportunity for a safe isolation during heart surgery or even by catheterization. Interestingly, there was a significant increase in the number of BCRP + /CD31 2 cells in ischaemic compared with non-ischaemic ventricle. These results might reflect repair mechanisms which are activated after ischaemic events. In the murine setting, Pfister et al. 26 found that in vitro cardiomyogenic differentiation was observed exclusively in cardiac SP cells lacking CD31. For the human heart, a potential activation and mobilization of these CRPC in vivo by a local cytokine application as proposed by Urbanek et al. 25 might be optimized by a detailed CRPC mapping. The localization of BCRP + cells in non-ischaemic atria is in line with previous reports on the special role of the atria for c-kit + cells, described as protected niches located in anatomical areas exposed to low levels of wall stress, 27 with higher numbers of cardiac progenitor cells produced from right atrial tissue than obtained from other parts of the heart. 28 Meissner et al. 21 reported that ABCG2 is variably expressed in endothelial cells of the human heart. In our study, BCRP + / CD31 + endothelial cells 24, 26 were detected in all areas of the heart within capillaries and small arterioles. Higher numbers were detected in ischaemic as well as in non-ischaemic atria and after myocardial infarction, increased numbers were identified in the ischaemic area of the ventricle, probably supporting angiogenesis. Only a few BCRP + /CD31 2 cells expressed the cardiac marker titin. Likewise, individual BCRP + /CD31 2 cells were found to express other cardiac markers such as sarcomeric a-actinin and Nkx2.5; however, their frequency was not quantified in this study. At the same time, the absence of expression of Oct-3/4, SSEA-3, and SSEA-4 in BCRP + cells clearly indicates the lack of pluripotency. On the basis of these data, we assume that the BCRP + cell population described in this study might represent an already committed mesodermal progenitor state, as described by Ott et al. 29 As we did not detect human BCRP + /Sca-1 + cells, we conclude that the progenitor cell population described in our study is not identical to the Sca-1 + progenitor population found earlier in the human heart. 17 However, we cannot rule out heterogeneous Sca-1 expression in a subset of human BCRP + cells, as was described for the mouse heart.
26,30
C-kit 1 cells in the adult human heart
Additionally, we were able to confirm the presence of c-kit + CRPC in the adult myocardium, 16,31 with higher frequencies (up to five-fold) in the ischaemic ventricles and much lower numbers in the non-ischaemic myocardium. A comparison of progenitor cell frequencies observed in the human heart is difficult. however, we did not observe full differentiation into functional beating cardiomyocytes or other cardiac cell types. Therefore, it remains unclear whether they could represent cardiac progenitor cells in the human heart. This might argue for fundamental species differences with respect to differentiation potential and the physiological role of cardiac BCRP + progenitor cells, similar to differences in differentiation capacity observed for MSCs or cardiospheres. 22, 41 Although the significantly increased number of those cells in the ischaemic myocardium strongly suggests an important role in regeneration processes, the formation of functional de novo myocardium from human cardiac BCRP + progenitor cells appears rather unlikely. Clearly, further studies will be needed to fully characterize the regenerative potential of this interesting cell population from the adult human heart.
Conclusion
In conclusion, we were able to demonstrate that BRCP + /CD31 2 cells are more abundant in the human heart than their c-kit + counterparts. In the non-ischaemic heart, they are preferentially located in the atria. Following ischaemia, their numbers are increased significantly and, most interestingly, the highest change can be found in the left ventricle. At the same time, also the number of these BCRP + cells expressing the cardiac marker titin is highest in the left ventricle. Breast cancer resistance protein + cells could be isolated from the human heart and adopted certain markers of immature cardiomyocytes in vitro, but without differentiation into beating cells. Therefore, our data might provide a valuable snapshot at cardiac progenitor cells after acute ischaemia, even though absolute numbers of cells acquiring a myocardial phenotype are low and the overall impact on cardiac regeneration in vivo has to be investigated in the future.
Study limitations
In this proof of concept study, the patient cohort displayed certain heterogeneity, and only a minimal data set was collected for each patient with regard to demographic profiling. Therefore, in subsequent studies when including higher numbers of patients, it may be of value to correlate more specific patient characteristics (including complete medication) with the expression and frequencies of BCRP cells. Additionally, we restricted our study to c-kit 
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